BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2232 related articles for article (PubMed ID: 25935633)

  • 1. Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease.
    Angulo P; Kleiner DE; Dam-Larsen S; Adams LA; Bjornsson ES; Charatcharoenwitthaya P; Mills PR; Keach JC; Lafferty HD; Stahler A; Haflidadottir S; Bendtsen F
    Gastroenterology; 2015 Aug; 149(2):389-97.e10. PubMed ID: 25935633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study.
    Vilar-Gomez E; Calzadilla-Bertot L; Wai-Sun Wong V; Castellanos M; Aller-de la Fuente R; Metwally M; Eslam M; Gonzalez-Fabian L; Alvarez-Quiñones Sanz M; Conde-Martin AF; De Boer B; McLeod D; Hung Chan AW; Chalasani N; George J; Adams LA; Romero-Gomez M
    Gastroenterology; 2018 Aug; 155(2):443-457.e17. PubMed ID: 29733831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Value of Non-Invasive Fibrosis and Steatosis Tools, Hepatic Venous Pressure Gradient (HVPG) and Histology in Nonalcoholic Steatohepatitis.
    Sebastiani G; Alshaalan R; Wong P; Rubino M; Salman A; Metrakos P; Deschenes M; Ghali P
    PLoS One; 2015; 10(6):e0128774. PubMed ID: 26083565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diabetes impacts prediction of cirrhosis and prognosis by non-invasive fibrosis models in non-alcoholic fatty liver disease.
    Bertot LC; Jeffrey GP; de Boer B; MacQuillan G; Garas G; Chin J; Huang Y; Adams LA
    Liver Int; 2018 Oct; 38(10):1793-1802. PubMed ID: 29575516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histologic Scores for Fat and Fibrosis Associate With Development of Type 2 Diabetes in Patients With Nonalcoholic Fatty Liver Disease.
    Björkström K; Stål P; Hultcrantz R; Hagström H
    Clin Gastroenterol Hepatol; 2017 Sep; 15(9):1461-1468. PubMed ID: 28479500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.
    Taylor RS; Taylor RJ; Bayliss S; Hagström H; Nasr P; Schattenberg JM; Ishigami M; Toyoda H; Wai-Sun Wong V; Peleg N; Shlomai A; Sebastiani G; Seko Y; Bhala N; Younossi ZM; Anstee QM; McPherson S; Newsome PN
    Gastroenterology; 2020 May; 158(6):1611-1625.e12. PubMed ID: 32027911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration.
    Patel YA; Gifford EJ; Glass LM; Turner MJ; Han B; Moylan CA; Choi S; Suzuki A; Provenzale D; Hunt CM
    Dig Dis Sci; 2018 Sep; 63(9):2259-2266. PubMed ID: 29779083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD.
    Hagström H; Nasr P; Ekstedt M; Hammar U; Stål P; Hultcrantz R; Kechagias S
    J Hepatol; 2017 Dec; 67(6):1265-1273. PubMed ID: 28803953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up.
    Ekstedt M; Hagström H; Nasr P; Fredrikson M; Stål P; Kechagias S; Hultcrantz R
    Hepatology; 2015 May; 61(5):1547-54. PubMed ID: 25125077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis With Liver Fibrosis as Predictors of New-Onset Diabetes Mellitus in People With HIV: A Longitudinal Cohort Study.
    Han WM; Apornpong T; Lwin HMS; Thammapiwan S; Boonrungsirisap J; Gatechompol S; Ubolyam S; Tangkijvanich P; Kerr SJ; Avihingsanon A
    Clin Infect Dis; 2023 Dec; 77(12):1687-1695. PubMed ID: 37477514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options.
    Younossi Z; Stepanova M; Sanyal AJ; Harrison SA; Ratziu V; Abdelmalek MF; Diehl AM; Caldwell S; Shiffman ML; Schall RA; McColgan B; Subramanian GM; Myers RP; Muir A; Afdhal NH; Bosch J; Goodman Z
    J Hepatol; 2018 Dec; 69(6):1365-1370. PubMed ID: 30144554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease.
    Angulo P; Bugianesi E; Bjornsson ES; Charatcharoenwitthaya P; Mills PR; Barrera F; Haflidadottir S; Day CP; George J
    Gastroenterology; 2013 Oct; 145(4):782-9.e4. PubMed ID: 23860502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Bariatric Surgery With Major Adverse Liver and Cardiovascular Outcomes in Patients With Biopsy-Proven Nonalcoholic Steatohepatitis.
    Aminian A; Al-Kurd A; Wilson R; Bena J; Fayazzadeh H; Singh T; Albaugh VL; Shariff FU; Rodriguez NA; Jin J; Brethauer SA; Dasarathy S; Alkhouri N; Schauer PR; McCullough AJ; Nissen SE
    JAMA; 2021 Nov; 326(20):2031-2042. PubMed ID: 34762106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease.
    Kleiner DE; Brunt EM; Wilson LA; Behling C; Guy C; Contos M; Cummings O; Yeh M; Gill R; Chalasani N; Neuschwander-Tetri BA; Diehl AM; Dasarathy S; Terrault N; Kowdley K; Loomba R; Belt P; Tonascia J; Lavine JE; Sanyal AJ;
    JAMA Netw Open; 2019 Oct; 2(10):e1912565. PubMed ID: 31584681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SAF score and mortality in NAFLD after up to 41 years of follow-up.
    Hagström H; Nasr P; Ekstedt M; Kechagias S; Stål P; Bedossa P; Hultcrantz R
    Scand J Gastroenterol; 2017 Jan; 52(1):87-91. PubMed ID: 27616339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of De Novo Nonalcoholic Fatty Liver Disease After Liver Transplantation and Associated Fibrosis.
    Galvin Z; Rajakumar R; Chen E; Adeyi O; Selzner M; Grant D; Sapisochin G; Greig P; Cattral M; McGilvray I; Ghanekar A; Selzner N; Lilly L; Patel K; Bhat M
    Liver Transpl; 2019 Jan; 25(1):56-67. PubMed ID: 30609189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors for biopsy-proven advanced non-alcoholic fatty liver disease in the Veterans Health Administration.
    Patel YA; Gifford EJ; Glass LM; McNeil R; Turner MJ; Han B; Provenzale D; Choi SS; Moylan CA; Hunt CM
    Aliment Pharmacol Ther; 2018 Jan; 47(2):268-278. PubMed ID: 29115682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management.
    McPherson S; Hardy T; Henderson E; Burt AD; Day CP; Anstee QM
    J Hepatol; 2015 May; 62(5):1148-55. PubMed ID: 25477264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disease progression of nonalcoholic steatohepatitis in Taiwanese patients: a longitudinal study of paired liver biopsies.
    Lin TY; Yeh ML; Huang CF; Huang CI; Dai CY; Hsieh MH; Chen SC; Huang JF; Yu ML; Chuang WL
    Eur J Gastroenterol Hepatol; 2019 Feb; 31(2):224-229. PubMed ID: 30308578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Collagen proportionate area is an independent predictor of long-term outcome in patients with non-alcoholic fatty liver disease.
    Buzzetti E; Hall A; Ekstedt M; Manuguerra R; Guerrero Misas M; Covelli C; Leandro G; Luong T; Kechagias S; Manesis EK; Pinzani M; Dhillon AP; Tsochatzis EA
    Aliment Pharmacol Ther; 2019 May; 49(9):1214-1222. PubMed ID: 30882933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 112.